MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

Начало・Списък с акции・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Отворен

СекторЗдравеопазване

45.68 -0.98

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

44.61

Максимум

46.16

Ключови измерители
By Trading Economics
Приходи	-1.1B 1.3B
Продажби	1.1B 12B
P/E Средно за сектора	17.731 35.739
EPS	1.46
Дивидентна доходност	5.58
Марж на печалбата	10.702
Служители	34,100
EBITDA	-1.2B 3.3B

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+7.67% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	5.58% 3.08%
Следващи печалби	30.10.2025 г.
Следваща дата на дивидент	3.11.2025 г.
Следваща дата на екс-дивидент	3.10.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-5.5B 90B
Предишно отваряне	46.66
Предишно затваряне	45.68

Настроения в новините

By Acuity

45%

55%

137 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

N/A / 50.57 Подкрепа & съпротива

Bristol-Myers Squibb Co. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.07.2025 г., 11:14 ч. UTC

Печалби

Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q

2.06.2025 г., 11:48 ч. UTC

Значими двигатели на пазара

BioNTech Sets Cancer-Drug Deal With Bristol Myers Potentially Worth More Than $11 Billion

4.08.2025 г., 11:59 ч. UTC

Печалби

BioNTech Stock Rises as Drugmaker Beats Earnings Expectations. -- Barrons.com

31.07.2025 г., 11:54 ч. UTC

Печалби

Bristol Myers Cuts Full-Year Adjusted View, But Raises Rev Estimates on Strong 2Q - Update

31.07.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 2Q Growth Portfolio Revenue Rose 18% to $6.6B >BMY

31.07.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb Cuts 2025 View To Adj EPS $6.35-Adj EPS $6.65 Vs Prior View $6.70-$7.00 >BMY

31.07.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 2Q Adjusted Gross Margin 72.6% >BMY

31.07.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 2Q Adj EPS $1.46 >BMY

31.07.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 2Q International Revenue Rose 10% to $3.75B >BMY

31.07.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb Raises 2025 View To Rev $46.5B-$47.5B From Prior View $45.8B-$46.8B >BMY

31.07.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Expected Continued Generic Impact Across Remainder of Legacy Portfolio, as Well as Impacts From U.S. Medicare Part D Redesign >BMY

31.07.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: In Back Half of Year, Focused on Advancing Transformational Medicines and Delivering on Our Growth Portfolio and Important Pipeline Opportunities to Shape Our Growth Trajectory >BMY

31.07.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: Raised 2025 Rev Guidance Reflecting Strength of Growth Portfolio, Better-Than-Expected Legacy Portfolio Sales in 2Q and Favorable Impact of About $200M Related to Foreign Exchange Rates >BMY

31.07.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: Latest 2Q Includes Net Impact of Loss of 57c/Shr Due to Acquired IPRD Charge Associated With BioNtech Strategic Partnership >BMY

31.07.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Immuno-Oncology Portfolio, Breyanzi, Reblozyl and Camzyos, and Reflects Continued Strength of Cobenfy >BMY

31.07.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 2Q Legacy Portfolio Rev Fell 14% to $5.67B >BMY

31.07.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 2Q Gross Margin 72.5% >BMY

31.07.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 2Q Rev $12.27B >BMY

31.07.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Beats Earnings Expectations. It's Still Optimistic About New Schizophrenia Drug. -- Barrons.com

31.07.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: Revised 2025 Adj EPS Guidance Inclusive of BioNTech Acquired IPRD Chg in 2Q >BMY

31.07.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 2Q U.S. Revenue Fell 3% to $8.52B >BMY

31.07.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 2Q EPS 64c >BMY

12.06.2025 г., 14:20 ч. UTC

Придобивния, сливания и поглъщания

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

13.05.2025 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

2seventy bio: Bristol Myers Squibb Completes Acquisition of 2seventy

12.05.2025 г., 22:14 ч. UTC

Топ новини

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12.05.2025 г., 18:45 ч. UTC

Топ новини

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12.05.2025 г., 17:14 ч. UTC

Топ новини

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

12.05.2025 г., 12:07 ч. UTC

Пазарно говорене

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

7.05.2025 г., 20:09 ч. UTC

Печалби

Придобивния, сливания и поглъщания

2seventy Bio 1Q Rev $22.9M >TSVT

7.05.2025 г., 20:08 ч. UTC

Печалби

Придобивния, сливания и поглъщания

2seventy Bio 1Q EPS 1c >TSVT

Сравнение с други в отрасъла

Ценова промяна

Bristol-Myers Squibb Co. Прогноза

Ценова цел

By TipRanks

7.67% нагоре

12-месечна прогноза

Среден 51.07 USD 7.67%

Висок 65 USD

Нисък 34 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за Bristol-Myers Squibb Co. през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

20 ratings

Купи

Задържане

Продай

Според 20 анализатори, дали борсови рейтинги на Bristol-Myers Squibb Co. през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 50.57Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

137 / 371 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.